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Arylimidamide (AIA) compounds containing two pyridylimidamide terminal groups (bis-AIAs) possess
outstanding in vitro antileishmanial activity, and the frontrunner bis-AIA DB766 (2,5-bis[2-(2-iso-
propoxy)-4-(2-pyridylimino)aminophenyl]furan) is active in visceral leishmaniasis models when given
orally. Eighteen compounds containing a single pyridylimidamide terminal group (mono-AIAs) were
synthesized and evaluated for their antileishmanial potential. Six of these compounds exhibited sub-
micromolar potency against both intracellular Leishmania donovani and Leishmania amazonensis
amastigotes, and three of these compounds also displayed selectivity indexes of 25 or greater for the
parasites compared to a J774 macrophage cell line. When given orally at a dose of 100 mg/kg/day for five
days, compound 1b (N-(3-isopropoxy-4-(5-phenylfuran-2-yl)phenyl)picolinimidamide methanesul-
fonate) reduced liver parasitemia by 46% in L. donovani-infected mice. Mono-AIAs are thus a new class
of candidate molecules for antileishmanial drug development.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).With well over one million new cases and 20,000–40,000
deaths annually,1 leishmaniasis is the second most prevalent infec-
tious disease transmitted by a vector in terms of morbidity and
mortality.2 Leishmaniasis is a spectrum of disease caused by infec-
tion with approximately twenty species of Leishmania protozoa.
Among the major clinical forms, visceral leishmaniasis (VL) is the
most severe and is fatal if left untreated, while cutaneous leishma-
niasis (CL) is typically self-healing. Nevertheless, drugs are fre-
quently used to treat CL to limit scarring from cutaneous lesions,
to speed the time to cure, and to prevent the development of the
potentially disfiguring mucocutaneous leishmaniasis manifesta-
tion. The current drugs against leishmaniasis include pentavalent
antimonials, amphotericin B (AmB), miltefosine and paromomycin,
but they all suffer from one or more weaknesses, such as parasite
resistance, toxicity, high cost, and an inconvenient route of admin-
istration.2 New oral antileishmanial drugs are thus needed to over-
come these issues and provide better treatment options against
Leishmania infections.We have demonstrated that bis-arylimidamides (bis-AIAs), a
series of compounds containing two pyridylimidamide terminal
groups, possess excellent in vitro and promising in vivo antileish-
manial activity. In the AIAs, the imino group is bound to an anilino
nitrogen atom, lowering the pKa of the amidine and increasing the
lipophilicity of the molecule compared to a dicationic diamidine
compound such as pentamidine.3 DB766 and DB1960, the
hydrochloride and mesylate salts of 2,5-bis[2-(2-isopropoxy)-4-
(2-pyridylimino)aminophenyl]furan, respectively, display IC50 val-
ues similar to AmB against both intracellular Leishmania donovani
and intracellular Leishmania amazonensis and provide dose-depen-
dent reduction of liver parasitemia in a mouse model of visceral
leishmaniasis when administered orally.3,4 Unfortunately, DB766
and DB1960 lack the therapeutic window required for advance-
ment as clinical monotherapy candidates against visceral
leishmaniasis.4
As part of a broader study, we previously reported two terphenyl
AIAs containing a single pyridylimidamide group (mono-AIAs) that
displayed promising activity against intracellular L. amazonensis.5
We hypothesize that lower molecular weight mono-AIAs may have
improved pharmacokinetic properties and could display decreased
2552 X. Zhu et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2551–2556toxicity to animals compared to bis-AIAs. The synthesis and evalu-
ation of such a group of molecules is reported here to test this
hypothesis.
Most of the mono-AIAs investigated were synthesized as out-
lined in Scheme 1 using methodology similar to that employed
previously for making bis-AIAs.6–8 The first step involved Stille
coupling between tributyl(furan-2-yl)stannane and various substi-
tuted 4-bromonitrobenzenes. Bromination of the 2-(4-nitro-
phenyl)furan analogs with NBS at room temperature yielded the
corresponding 5-bromo-2-(4-nitrophenyl)furans. Subsequent
reaction of the 5-bromofurans under either Stille or Suzuki condi-
tions provided the 2-(4-nitrophenyl)-5-arylfuran intermediates.
Catalytic hydrogenation of the nitro group of the diarylfurans gave
the corresponding amino analogs. Finally, reaction of the amino
diarylfurans with either 2-pyridyl or 2-pyrimidyl thioimidate ana-
logs produced, after salt formation, the mono-AIAs 1a–p. Most tar-
get compounds were prepared as the more soluble mesylate salt.4
Hydrochloride salts were made for 1a and 1d because of the hygro-
scopic nature of the corresponding mesylates.
The synthesis of triazole 2 employed the Huisgen cycloaddition
process under typical ‘Click chemistry’ conditions to yield the key
nitro intermediate 4-(2-isopropoxy-4-nitrophenyl)-1-(4-methoxy-
phenyl)-1H-1,2,3-triazole as shown in Scheme 2.9 The subsequent
steps are similar to those of Scheme 1 but the reduction of the nitro
group to the amine in this case was achieved using Raney-nickel
and hydrazine.10
The synthesis of the oxazole 3 is presented in Scheme 3 and
employed (p-toluenesulfonyl)methyl isocyanide chemistry for the
formation of 5-(2-isopropoxy-4-nitrophenyl)oxazole.11 The latter
compound was converted into 2-phenyl-5-(2-isopropoxy-4-nitro-
phenyl)oxazole by Pd/Cu catalyzed arylation with iodoben-
zene.12,13 The conversion of the nitro analog into the mono-AIA 3
followed methodology previously described in Scheme 1.
Methods employed for the evaluation of the efficacy of mono-
AIA target compounds against intracellular L. amazonensis14 and
intracellular L. donovani15 and for toxicity to murine J774
macrophages16 have been described previously. In these assays,
the reference compound amphotericin B displayed IC50 values
of 40 ± 3 nM (mean ± standard error, n = 15) and 120 ± 10 nM
(mean ± standard error, n = 26) against L. donovani and
L. amazonensis, respectively, while the cytotoxicity standard
podophyllotoxin showed an IC50 value of 24 ± 5 nM (mean ±
standard error, n = 15) against J774 macrophages. For ease in illus-
trating the antileishmanial SAR of this series of compounds, the
central phenyl ring, the linker, and the terminal phenyl ring are
referred to as rings A, B, and C, respectively (Fig. 1).
For derivatives bearing substitutions at the 5 position of the
furan ‘B’ ring (at the position occupied by the C ring in Fig. 1),Br
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Scheme 1. Reagents and conditions: (a) Pd(PPh3)4, 1,4-dioxane, reflux, 68–79%; (b) NB
(PPh3)4, toluene, Na2CO3, H2O, 80 C, 59–79%; (d) H2, Pd/C, EtOAc, EtOH, 68–98%; (
(ii) HCI/EtOH or CH3SO3H, CH2CI2, 55–73%.we observed that the most active compound was 1b, where the
C ring is a phenyl group. Compound 1b displayed IC50 values of
310 and 130 nM against intracellular L. donovani and intracellular
L. amazonensis, respectively (Table 1). Activity was maintained
when the phenyl ring was replaced with a furan ring (1d). The
antileishmanial potency decreased by 4–20 fold when this position
was substituted with other groups, however, such as hydrogen
(1a), 5-pyrimidyl (1c), 3-pyridyl (1e), or 4-pyridyl (1f).
The addition of a methoxy group or a fluorine atom at position
R2 or a methoxy group at position R1 of phenyl ring C led to
decreased antileishmanial potency in both the intracellular
L. amazonensis and L. donovani assays (Table 2). In the series of
compounds bearing different substitutions on phenyl ring ‘A’, the
cyclopentyloxy substituted derivative 1kwas the most active com-
pound, with IC50 values comparable to that of 1b and amphotericin
B (Table 3). As the size of the alkoxy substituent increased from
methoxy (1m) to ethoxy (1l) to isopropoxy (1b) and cyclopenty-
loxy (1k), antileishmanial activity increased, but switching the
position of the isopropoxy substitution on the ‘A’ ring (1j) resulted
in a loss of antiparasitic activity. Replacement of furan as the ‘B’
ring with other heterocycles (thiophene 1o, triazole 2, or oxazole
3) lowered the antileishmanial activity, with 3 being intermediate
in potency between the highly active 1b and the moderately active
2 and 1o (Table 4). Replacement of the 2-pyridyl terminal group
with a 2-pyrimidyl group (1p) resulted in a reduction in potency
against L. amazonensis but not against L. donovani (Table 4). In
the host cell counterscreen, the mono-AIAs exhibited IC50 values
ranging from 5300 to >50,000 nM against murine J774 macro-
phages, resulting in selectivity indexes (IC50 vs J774 macro-
phages/IC50 vs Leishmania) of 2.4–100 against intracellular L.
amazonensis and 3.1–76 against intracellular L. donovani in vitro.
Among these 18 mono-AIAs, 1b, 1d, and 1k displayed outstand-
ing antileishmanial potency and good selectivity for intracellular
Leishmania compared to J774 murine macrophages (selectivity
indexes P25), warranting the in vivo evaluation of these deriva-
tives. Compounds 1b, 1d, and 1k were dissolved in water and
administered to healthy BALB/c mice for assessment of their
in vivo toxicity. Each of these compounds was well tolerated when
administered by the i.p. route at 30 mg/kg/day for 5 days and were
thus evaluated at this dose in a murine model of visceral leishma-
niasis.4 Animals were infected with L. donovani LV82 promastig-
otes and then treated with different compounds one week post
infection for five consecutive days. These mice were euthanized
two weeks post infection and liver smear slides were prepared
for the microscopic determination of parasitemia. When given at
the dose listed above, administration of 1b, 1d, and 1k resulted
in 37%, 13%, and 20% suppression of liver parasitemia, respectively,
compared to untreated control groups (Fig. 2A, B). As the mostO O
O2N
R1
Br
O
O2N
R1
ArO
R1
Ar
b
c
d
R2
R2R2
S, DMF, rt, 72–85%; (c) ArSn(n-Bu)3, Pd(PPh3)4, 1,4-dioxane, reflux or ArB(OH)2, Pd
e) (i) S-(2-naphthylmethyl)-2-pyridylthioimidate hydrobromide, EtOH/CH3CN, rt,
CH3
NO2
O N
O
O2N
O N
O
O2N
O
N
O
N
H
O
NH
N
CH2Br
NO2
O
CHO
NO2
Oa b c d
N
O
H2N
O
e
f
3
Scheme 3. Reagents and conditions: (a) NBS, AIBN, CCI4. light, 89%; (b) Ag2O, pyridine N-oxide, MeCN, 81%; (c) toluenesulfonylmethyl isocyanide, K2CO3, MeOH, 73%;
(d) iodobenzene, Pd(OAc)2, Cs2CO3, Cul, DMF, 160 C, 95%; (e) Ra-Ni, NH2NH2, MeOH, 50 C, 94%; (f) (i) S-(2-naphthylmethyl)-2-pyridylthioimidate hydrobromide,
EtOH/CH3CN, rt, (ii) CH3SO3H, CH2CI2, 71%.
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Scheme 2. Reagents and conditions: (a) (i) ethynyltrimethylsilane, PdCI2(PPh3)2/Cul,PPh3/Et3N, 85%, (ii) K2CO3, MeOH, 94%; (b) 4-methoxyphenylazide, CuSO4-5H2O,
L-ascorbate, t-BuOH, H2O, 38%; (c) Ra-Ni, NH2NH2, MeOH, 50 C, 89%; (d) (i) S-(2-naphthylmethyl)-2-pyridylthioimidate, EtOH, CH3CN, rt, (ii) CH3SO3H, CH2CI2, 61%.
Table 1
In vitro activity of compounds (1a–f) against intracellular Leishmania amastigotes and
murine J774 macrophages
ON
H
R
NH
N
O
Compound R IC50a (nM)
Intracellular L.
amazonensis
Intracellular L.
donovani
J774
macrophages
1a H 2100 ± 200 2400 ± 300 22,000 ± 4000
1b 130 ± 30 310 ± 10 13,000 ± 1000
1c
N
N
1100 ± 300 2100 ± 400 >20,000
1d
O
250 ± 10 340 ± 50 8500 ± 800
1e
N
900 ± 230b 1200 ± 100 >50,000
1f
N
2700 ± 200b 2600 ± 100 22,000 ± 1000
a The values are means ± standard errors of at least three independent
experiments.
b The values are the means ± range of two independent experiments.
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Figure 1. Mono-AIA scaffold.
X. Zhu et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2551–2556 2553effective of these three compounds when given i.p., the oral effi-
cacy of 1b was also evaluated in the murine visceral leishmaniasis
model. Compound 1b reduced liver parasitemia by 46% at an oral
dose of 100 mg/kg/day for five days compared to the control group
(Fig. 2C). The in vivo antileishmanial efficacy of 1b is thus similar to
that of DB1960 and lower than that of DB766 when the compounds
are administered orally at 100 mg/kg in five daily doses.3,4 When
given to infected mice at a dose of 10 mg/kg/day for five days by
either the i.p. or oral route, miltefosine administration resulted in
>90% inhibition of liver parasitemia, consistent with our previous
observations.4,15
To confirm the exposure and accumulation of 1b in target
organs after oral administration, plasma and tissue concentrations
of this compound were determined at 1, 2 and 24 h after a single
oral dose at 100 lmol/kg (or 40 mg/kg) in mice. Compound 1b
accumulated in the target organs such as liver and spleen at higher
concentrations (C1h = 12.6 and 4.7 lM, respectively) than in the
plasma (C1h = 1.9 lM) (Fig. 3). At 24 h post dose, 1b concentra-
tions decreased substantially to 0.14 lM in the plasma and 0.6–
0.7 lM in the liver and spleen.
Our efforts to explore the mechanism of antileishmanial action
of the bis-AIAs led to the observation that DB766 is synergistic
with posaconazole against Leishmania donovani in vitro17; other
investigators reported in vitro antileishmanial synergy between
posaconazole and the squalene synthase inhibitor E5700.18 A
Table 4
In vitro activities of compounds 1b, 1o, 1p, 2, and 3 against intracellular Leishmania amas
N
H
NH
O
R1
X
Compound X R1 R2
Intracel
1b
O
2-Pyridyl H 130 ± 30
1o
S
2-Pyridyl H 2300 ± 3
1p
O
2-Pyrimidyl H 650 ± 16
2
NN
N 2-Pyridyl OCH3 2900 ± 1
3
N
O
2-Pyridyl H 590 ± 60
a The values are means ± standard errors of at least three independent experiments.
b The value is the mean ± range of two independent experiments.
Table 3
In vitro activity of compounds 1b, 1j–n against intracellular Leishmania amastigotes and m
N
H
NH
N
R1
R2
Compound R1 R2
Intracellular L.
1b OCH(CH3)2 H 130 ± 30
1j H OCH(CH3)2 1600 ± 300
1k OCH(CH2)4 H 140 ± 10
1l OCH2CH3 H 980 ± 70b
1m OCH3 H 3700 ± 1300b
1n CF3 H >10,000b
a The values are means ± standard errors of at least three independent experiments.
b The values are the means ± range of two independent experiments.
Table 2
In vitro activity of compounds 1b, 1g–i against intracellular Leishmania amastigotes
and murine J774 macrophages
ON
H
NH
N
O R1
R2
Compound R1 R2 IC50a (nM)
Intracellular L.
amazonensis
Intracellular
L. donovani
J774
macrophages
1b H H 130 ± 30 310 ± 10 13,000 ± 1000
1g H OCH3 820 ± 310 900 ± 150 6700 ± 900
1h H F 920 ± 190 1100 ± 100 8000 ± 100
1i OCH3 H 1400 ± 200 1300 ± 100 5300 ± 1000
a The values are means ± standard errors of at least three independent
experiments.
2554 X. Zhu et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2551–2556combination study with 1b and posaconazole was thus performed
against intracellular L. amazonensis amastigotes. While azoles have
been used to treat CL,19,20 some of these compounds exhibit low
potency against certain Leishmania species in vitro.21,22 We found
this to be true for posaconazole against intracellular L. amazonensis
under the conditions of our assay (IC50 > 10 lM; posaconazole
exhibits low solubility at higher concentrations), making standard
isobologram analysis impossible in this case. Instead, the method
described by Peters et al.23 was employed to determine whether
posaconazole enhances the potency of 1b. Figure 4 demonstrates
that this azole augmented the potency of the mono AIA 1b against
intracellular L. amazonensis, with 1b displaying an IC50 value that is
fivefold lower in the presence of 8 lM posaconazole compared to
the IC50 of this AIA in the absence of the azole. IC50 values for 1b
(DB2002) alone in this experiment and in the presence of 8 lM
posaconazole are 0.26 ± 0.05 and 0.055 ± 0.015 lM, respectively.
We are aware that de Macedo-Silva et al. reported an IC50 value
of 1.6 lM for posaconazole against intracellular L. amazonensis.24
Although both assays involved incubating infected murinetigotes and murine J774 macrophages
R2
IC50a (nM)
lular L. amazonensis Intracellular L. donovani J774 macrophages
310 ± 10 13,000 ± 1000
00b 2200 ± 500 6900 ± 400
0 440 ± 60 12,000 ± 1000
00 1600 ± 200 16,000 ± 3000
1000 ± 0 24,000 ± 1000
urine J774 macrophages
O
IC50a (nM)
amazonensis Intracellular L. donovani J774 macrophages
310 ± 10 13,000 ± 1000
1400 ± 300 13,000 ± 1000
170 ± 40 13,000 ± 3000
850 ± 170 6600 ± 600
1400 ± 300 9000 ± 2000
6100 ± 1400 >20,000
Miltefosine 
10 mg/kg ip
In
hi
bi
tio
n 
(%
)
0
20
40
60
80
100
120
1b
30 mg/kg ip
98
37
    Milt 
10 mg/kg 
In
hi
bi
tio
n 
(%
)
0
20
40
60
80
100
120
1b
50 mg/kg 
1b
100 mg/kg 
96
37
46
    Milt 
10 mg/kg 
In
hi
bi
tio
n 
(%
)
0
20
40
60
80
100
120
1k
30 mg/kg 
    1d
30 mg/kg 
99
20 13
A CB
i.p. i.p. p.o.*
* *
*
* *
  #
Figure 2. In vivo efficacy of mono-AIAs in the murine visceral leishmaniasis model. Compounds were administered i.p. (A and B) or p.o. (C) once daily for 5 days to infected
mice. Results are presented as the percentage inhibition of liver parasitemia. Bars and error bars show the mean and standard deviation, respectively (n = 4) *p < 0.01,
compared to untreated control, #p < 0.05, compared to untreated control.
Figure 3. Concentration of 1b in liver ( ), spleen ( ), kidney ( ), and plasma
( ) after oral administration at a dose of 100 lmol/kg (or 40 mg/kg) to mice. Bars
and error bars represent means and standard errors of triplicate determinations,
respectively.
Figure 4. In vitro interactions between 1b and posaconazole against intracellular L.
amazonensis. Results are presented as the IC50 of 1b alone and in different
combinations. Bars and error bars show the mean and standard deviation of three
independent experiments.
X. Zhu et al. / Bioorg. Med. Chem. Lett. 26 (2016) 2551–2556 2555peritoneal macrophages with posaconazole for 72 h, de Macedo-
Silva exposed peritoneal macrophages to L. amazonensis for a
shorter time compared to our studies prior to removing extracellu-
lar parasites (2 h vs overnight). Our studies with intracellular L.
donovani have indicated that the level of macrophage infection
influences the apparent in vitro antileishmanial activity of azoles
(A. Joice, unpublished data). Thus, a likely explanation for the dis-
crepancy between IC50 values for posaconazole against intracellu-
lar L. amazonensis in the two studies is the differences in assay
conditions employed.
In summary, eighteen mono-AIAs were synthesized and evalu-
ated for their antileishmanial activities. Compounds 1b, 1d and 1k
displayed the highest potency against intracellular L. amazonensis
and intracellular L. donovani amastigotes with their IC50 values
slightly higher than those of amphotericin B and DB766. These
three mono-AIAs were well tolerated in healthy mice, indicating
that mono-AIAs may be generally less toxic than bis-AIAs.8,25 Com-
pound 1b shows moderate in vivo antileishmanial efficacy in a
mouse model of visceral leishmaniasis. Furthermore, posaconazole
enhances the activity of this compound against intracellular L.
amazonensis amastigotes, consistent with our observations with
the bis-AIA DB766.17 Mono-AIAs are thus promising antileishma-
nial leads, and further optimization of this class of compounds to
improve their in vivo efficacy is needed. Given the in vitro activity
of the compound 1b/posaconazole combination, combining amono AIA with an azole drug could be a fruitful strategy for the
development of antileishmanial therapies.
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